{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:45:44Z","timestamp":1787507144894,"version":"build-2736575974"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T00:00:00Z","timestamp":1661385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    <jats:bold>Introduction:<\/jats:bold>\n                    Diarrhea-predominant irritable bowel syndrome (IBS-D) significantly decreases the quality of life of patients and their families, and affects patients\u2019 mental health. No specific western medications are available. Ancient classical Chinese medical texts have recognized Tongxie Yaofang (TXYF) as a therapy for diarrhea which is widely used in clinical practice. Standard TXYF prescription (S-TXYF) is composed of four herbal medicines:\n                    <jats:italic>Atractylodes macrocephala<\/jats:italic>\n                    Koidz. [Asteraceae;\n                    <jats:italic>Rhizoma Atractylodis Macrocephalae<\/jats:italic>\n                    .], Paeonia lactiflora Pall. [Ranunculaceae; Paeoniae Radix Alba], Citrus \u00d7 aurantium L. [Rutaceae; Citri Reticulatae Pericarpium] and Saposhnikovia divaricata (Turcz. ex Ledeb.) Schischk. [Umbelliferae\n                    <jats:italic>; Saposhnikoviae Radix<\/jats:italic>\n                    ]. This review aimed to evaluate the therapeutic effects and safety of S-TXYF for IBS-D.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    Eight English and Chinese electronic databases were searched from their inception to 25 December 2021 for randomized controlled trials (RCTs) comparing S-TXYF with placebo, western medications or no treatment for IBS-D. The primary outcome was the global improvement of IBS-D symptoms. Data were analyzed using Cochrane\u2019s Revman 5.4 software. Evidence certainty was assessed using the online GRADEpro tool for the primary outcome.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    Eleven RCTs involving 985 adults with IBS-D were included. For global improvement of symptoms, S-TXYF was superior to western medication and placebo (moderate evidence by GRADE). Regarding the improvement of stool consistency, stool frequency and abdominal pain, S-TXYF was significantly effective than placebo. In addition, S-TXYF was superior to western medication on improving the quality of life and relieving anxiety. Six trials reported adverse events: five of them reported (non-serious) adverse events occurred in both groups, and one trial reported that 3 cases with adverse events (constipation, elevation in liver-enzyme, nausea) occurred in S-TXYF group and 3 cases with adverse events (abdominal distension, nausea) occurred in placebo group.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Although current results showed that S-TXYF may have potential to treat IBS-D and its use appears to be safe, no a clear and confirmed conclusion can be drawn from our review as the overall inadequate design of the included trials reviewed. So more rigorous trials are warranted to establish confirmed evidence on its benefits and safety.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2022.904657","type":"journal-article","created":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T03:43:52Z","timestamp":1661399032000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Systematic review and meta-analysis of Chinese herbal formula Tongxie Yaofang for diarrhea-predominant irritable bowel syndrome: Evidence for clinical practice and future trials"],"prefix":"10.3389","volume":"13","author":[{"given":"Shi-Bing","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Juan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Yao","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Li","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Hong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Jia","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Qi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Tong","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Ping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,25]]},"reference":[{"key":"B1","first-page":"771","article-title":"The Spanish version of the SF-36 health survey (the SF-36 health questionnaire): An instrument for measuring clinical results","volume":"104","author":"Alonso","year":"1995","journal-title":"Med. Clin."},{"key":"B2","doi-asserted-by":"publisher","first-page":"8807","DOI":"10.3748\/wjg.v20.i27.8807","article-title":"Irritable bowel syndrome: A disease still searching for pathogenesis, diagnosis and therapy","volume":"20","author":"Bellini","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1001\/jama.280.18.1585","article-title":"Treatment of irritable bowel syndrome with Chinese herbal medicine: A randomized controlled trial","volume":"280","author":"Bensoussan","year":"1998","journal-title":"JAMA"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e7586","DOI":"10.1136\/bmj.e7586","article-title":"SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials","volume":"346","author":"Chan","year":"2013","journal-title":"BMJ"},{"key":"B5","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/apt.14817","article-title":"Randomised clinical trial: Tong-Xie-Yao-Fang granules versus placebo for patients with diarrhoea-predominant irritable bowel syndrome","volume":"48","author":"Chen","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.13193\/j.archtcm.2006.11.70.chugw.031","article-title":"Research and explanation of TXYF","volume":"11","author":"Chu","year":"2006","journal-title":"Study J. Tradit. Chin. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.16305\/j.1007-1334.2017.08.021","article-title":"Discussion on prescription origin of Tongxie Yao Fang and the syndrome corresponding to prescription","volume":"51","author":"Dai","year":"2017","journal-title":"Shanghai J. Tradit. Chin. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.pop.2017.07.009","article-title":"Irritable bowel syndrome: Epidemiology, pathophysiology, diagnosis, and treatment","volume":"44","author":"Defrees","year":"2017","journal-title":"Prim. Care"},{"key":"B9","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"B10","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.eujim.2013.07.011","article-title":"GP-TCM Unabridged guidelines for randomised controlled trials investigating Chinese herbal medicine (CHM)","volume":"6","author":"Flower","year":"2014","journal-title":"Eur. J. Integr. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1056\/NEJMra1607547","article-title":"Irritable bowel syndrome","volume":"376","author":"Ford","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1038\/ajg.2014.187","article-title":"American College of gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation","volume":"109","author":"Ford","year":"2014","journal-title":"Am. J. Gastroenterol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1046\/j.1365-2036.1997.142318000.x","article-title":"The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress","volume":"11","author":"Francis","year":"1997","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"What is \"quality of evidence\" and why is it important to clinicians?","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"B15","doi-asserted-by":"publisher","first-page":"702","DOI":"10.13703\/j.0255-2930.20190621-k0007","article-title":"Therapeutic effect of herb-separated moxibustion at Jinsuo (GV 8)-eight-diagram points on diarrhea-type irritable bowel syndrome of liver stagnation and spleen deficiency","volume":"40","author":"Hao","year":"2020","journal-title":"Chin. Acupunct. Mox."},{"key":"B16","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2020"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1111\/j.1365-2036.2005.02463.x","article-title":"Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact","volume":"21","author":"Hungin","year":"2005","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.13729\/j.issn.1671-7813.Z20200811","article-title":"Clinical application and progress of traditional Chinese and western medication in functional gastrointestinal diseases","volume":"35","author":"Jia","year":"2021","journal-title":"J. Pract. Tradit. Chin. Intern. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.13863\/j.issn1001-4454.2010.10.013","article-title":"Clinical study of Tongxie Yaofang granules on the expression of VIP and SP in colon mucosa of irritable bowel syndrome with diarrhea","volume":"33","author":"Kong","year":"2010","journal-title":"J. Chin. Med. Mat."},{"key":"B20","unstructured":"Clinical study of additional Tongxie Yaofang in treating irritable bowel syndrome of the type of diarrhea\n            LiG. C.\n          Guangzhou, ChinaGuangzhou Univ. Tradit. Chin. Med.2006"},{"key":"B21","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3969\/j.issn.1000-7156.2021.12.022","article-title":"Intervening effect of Tongxie Yaofang on gut microbiota in IBS-D rat with syndrome of liver-depression and spleen-deficiency","volume":"37","author":"Li","year":"2021","journal-title":"Shanxi Traidit. Chin. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s13063-022-06142-x","article-title":"Chinese herbal formula Tongxie Yaofang for diarrhea-predominant irritable bowel syndrome: study protocol for a randomized, multiple-blind, placebo-controlled trial","volume":"23","author":"Liang","year":"2022","journal-title":"Trials"},{"key":"B23","unstructured":"Therapeutic effect of Tongxie Yaofang on patients with diarrhea-predominant irritable bowel syndrome and its effect on the expressing of IL-1\u03b2 and IL-10\n            LinF.\n          Fuzhou, Fujian, ChinaFujian Univ. Tradit. Chin. Med.2019"},{"key":"B24","unstructured":"The effect of tong Xie Yao Fang on IBS-D patients and the association with level of 5-HT and 5-HT3 receptors mRNA in colonic mucosa\n            LinZ. Q.\n          Fuzhou, Fujian, ChinaFujian Med. Univ.2012"},{"key":"B25","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.cgh.2012.02.029","article-title":"Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis","volume":"10","author":"Lovell","year":"2012","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3969\/j.issn.1006-5687.2022.03.003","article-title":"Analysis of the mechanism of Tongxie Yaofang in the treatment of irritable bowel syndrome and depression based on network pharmacology","volume":"34","author":"Man","year":"2022","journal-title":"Tianjin Pharm."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1053\/j.gastro.2016.02.031","article-title":"Bowel disorders","author":"Mearin","year":"2016","journal-title":"Gastroenterology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S2468-1253(20)30217-X","article-title":"Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: A systematic review and meta-analysis","volume":"5","author":"Oka","year":"2020","journal-title":"Lancet. Gastroenterol. Hepatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s11655-009-0216-7","article-title":"Effect of Tongxie Yaofang Granule in treating diarrhea-predominate irritable bowel syndrome","volume":"15","author":"Pan","year":"2009","journal-title":"Chin. J. Integr. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1023\/a:1018831127942","article-title":"Quality of life in persons with irritable bowel syndrome: development and validation of a new measure","volume":"43","author":"Patrick","year":"1998","journal-title":"Dig. Dis. Sci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"641","DOI":"10.14148\/j.issn.1672-0482.2020.0641","article-title":"Effects of tong-xie-yao-fang on intestinal flora of rats with diarrhea lrritable bowel syndrome and its mechanism interpretation based on 16S rRNA sequencing","volume":"36","author":"Peng","year":"2020","journal-title":"Nanjing Univ. Tradit. Chin. Med."},{"key":"B32","volume-title":"Review manager (RevMan) [computer program]","year":"2020"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1111\/j.1572-0241.2008.02048.x","article-title":"Genetics of irritable bowel syndrome","volume":"103","author":"Saito","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"100","DOI":"10.4103\/0976-500X.72352","article-title":"CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials","volume":"1","author":"Schulz","year":"2010","journal-title":"J. Pharmacol. Pharmacother."},{"key":"B35","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.3969\/j.issn.1004-745X.2020.09.008","article-title":"The mechanism of Tongxie Yaofang decoction for diarrhoeal irritable bowel syndrome based on the net-work pharmacology","volume":"29","author":"Sun","year":"2020","journal-title":"JETCM"},{"key":"B37","unstructured":"The study on the clinical features of IBS-D and the treatment of liver-depression and spleen-deficiency\n            TangB.\n          Tianjin, ChinaTianjin Univ. Tradit. Chin. Med.2017"},{"key":"B38","doi-asserted-by":"publisher","first-page":"605","DOI":"10.13703\/j.0255-2930.20190818-k0004","article-title":"Efficacy and mechanism of acupuncture combined with Tongxieyaofang for diarrhea-type irritable bowel syndrome of liver depression and spleen deficiency","volume":"40","author":"Wang","year":"2020","journal-title":"Chin. Acupunct. Mox."},{"key":"B39","doi-asserted-by":"publisher","first-page":"107","DOI":"10.13422\/j.cnki.syfjx.20201221","article-title":"Clinical efficacy and mechanism of Tongxie Yaofang on patients with IBS-D of liver depression and spleen deficiency","volume":"26","author":"Yao","year":"2020","journal-title":"Chin. J. Exp. Tradit. Med. Form."},{"key":"B40","doi-asserted-by":"publisher","first-page":"154","DOI":"10.16808\/j.cnki.issn1003-7705.2020.10.062","article-title":"Effect of Tongxieyaofang on gut microbiota in rats with diarrhea-predominant irritable bowel syndrome with liver depression and spleen deficiency","volume":"36","author":"Zhang","year":"2020","journal-title":"Hunan J. Tradit. Chin. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.16448\/j.cjtcm.2017.0438","article-title":"Clinical observation in the treatment of irritable bowel syndrome (diarrhea type) with liver qi stagnation and spleen deficiency type by the method of Tongxie Yaofang","volume":"29","author":"Zhang","year":"2017","journal-title":"Clin. J. Tradit. Chin. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"4893876","DOI":"10.1155\/2019\/4893876","article-title":"Clinical effects and safety of Tongxie Yaofang on diarrhea predominant irritable bowel syndrome: A meta-analysis of randomized trails","volume":"2019","author":"Zhou","year":"2019","journal-title":"Evid. Based. Complement. Altern. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3969\/j.issn.1000-1174.2020.12.032","article-title":"Research progress on the treatment of irritable bowel , syndrome by traditional Chinese and western medication","volume":"40","author":"Zhu","year":"2020","journal-title":"Chin. J. Coloproctology."},{"key":"B44","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S0033-3182(71)71479-0","article-title":"A rating instrument for anxiety disorders","volume":"12","author":"Zung","year":"1971","journal-title":"Psychosomatics"},{"key":"B45","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/archpsyc.1965.01720310065008","article-title":"A self-rating depression scale","volume":"12","author":"Zung","year":"1965","journal-title":"Arch. Gen. Psychiatry"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.904657\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T03:44:07Z","timestamp":1661399047000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.904657\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,25]]},"references-count":45,"alternative-id":["10.3389\/fphar.2022.904657"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.904657","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,25]]},"article-number":"904657"}}